We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Vertex Pharmaceuticals Inc | NASDAQ:VRTX | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.92 | 0.23% | 401.08 | 400.68 | 404.95 | 405.665 | 397.59 | 401.50 | 1,063,943 | 23:23:52 |
From May 2019 to May 2024
By Kimberly Chin
Vertex Pharmaceuticals Inc. reported higher profit for the first quarter, driven by strong revenue growth across its products.
The biopharmaceutical company said net profit was $653.1 million, up from $602.8 million a year earlier. On a per-share basis, profit rose to $2.49 from $2.29 a year ago. Adjusted earnings were $2.98 a share. Analysts polled by FactSet expected $2.44 a share, or $2.70 a share on an adjusted basis.
Total revenue rose to $1.72 billion from $1.52 billion a year earlier. Analysts were looking for $1.66 billion. Vertex saw an increase in sales from Kaftrio in Europe and Trikafta in the U.S.
Write to Kimberly Chin at kimberly.chin@wsj.com
(END) Dow Jones Newswires
April 29, 2021 16:27 ET (20:27 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year Vertex Pharmaceuticals Chart |
1 Month Vertex Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
